Marinus Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 165

Market Cap: $80.9M

Website

Introduction: Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Clinical Trials

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Phase 3

Withdrawn

Conditions: Refractory Status Epilepticus

Interventions: Drug: Ganaxolone
Drug: Placebo
Drug: Standard of care

First Posted Date: 2023-04-18

Last Posted Date: 2024-05-14

Lead Sponsor: Marinus Pharmaceuticals

Registration Number: NCT05814523

Locations: 🇧🇪
Hôpital Universitaire de Bruxelles - Hôpital Erasme, Bruxelles, Belgium
🇨🇿
Motol University Hospital, Prague, Czechia
🇫🇷
Hopital R. Salengro, Lille, France

and more 49 locations

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

Phase 2

Withdrawn

Conditions: Status Epilepticus

Interventions: Drug: IV Ganaxolone
Drug: IV Placebo

First Posted Date: 2023-03-07

Last Posted Date: 2024-05-07

Lead Sponsor: Marinus Pharmaceuticals

Registration Number: NCT05757544

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Phase 3

Conditions: Tuberous Sclerosis Complex

Interventions: Drug: Ganaxolone

First Posted Date: 2022-11-03

Last Posted Date: 2024-05-13

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 132

Registration Number: NCT05604170

Locations: 🇺🇸
UCLA Mattel Children's Hospital, TSC Center, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Penn State Children's Hospital, Hershey, Pennsylvania, United States

and more 56 locations

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Phase 3

Completed

Conditions: Tuberous Sclerosis Complex

Interventions: Drug: Ganaxalone
Drug: Placebo

First Posted Date: 2022-04-12

Last Posted Date: 2024-11-05

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT05323734

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇩🇪
Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 79 locations

Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old

Phase 3

Not yet recruiting

Conditions: CDKL5 Deficiency Disorder

Interventions: Drug: Placebo
Drug: Ganaxolone

First Posted Date: 2022-02-21

Last Posted Date: 2024-01-19

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT05249556

Ganaxolone Expanded Access Program Compassionate Use

Conditions: CDKL5 Disorder

First Posted Date: 2020-12-22

Last Posted Date: 2024-01-22

Lead Sponsor: Marinus Pharmaceuticals

Registration Number: NCT04678479

Randomized Therapy In Status Epilepticus

Phase 3

Completed

Conditions: Status Epilepticus

Interventions: Drug: Placebo
Drug: Ganaxolone

First Posted Date: 2020-05-18

Last Posted Date: 2024-10-15

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT04391569

Locations: 🇨🇦
Marinus Research Site, Saskatoon, Saskatchewan, Canada
🇺🇸
Marinus Research Site #1, Philadelphia, Pennsylvania, United States
🇺🇸
Marinus Research Site #2, Philadelphia, Pennsylvania, United States

Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)

Phase 2

Completed

Conditions: Tuberous Sclerosis

Interventions: Drug: Ganaxolone

First Posted Date: 2020-02-26

Last Posted Date: 2023-04-04

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT04285346

Locations: 🇺🇸
Marinus Research Site, Houston, Texas, United States

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

Phase 2

Completed

Conditions: PCDH19-Related Epilepsy

Interventions: Drug: Placebo
Drug: Ganaxolone

First Posted Date: 2019-03-07

Last Posted Date: 2023-06-26

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03865732

Locations: 🇵🇱
Marinus Research Site, Krakow, Poland

Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

Phase 3

Completed

Conditions: CDKL5 Deficiency Disorder

Interventions: Drug: ganaxolone
Drug: Placebo

First Posted Date: 2018-06-28

Last Posted Date: 2023-04-14

Lead Sponsor: Marinus Pharmaceuticals

Target Recruit Count: 101

Registration Number: NCT03572933

Locations: 🇬🇧
Marinus Research Site, London, United Kingdom
🇬🇧
Marinus Research Facility, Glasgow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy